Aspen Neuroscience: ARCH fund buys 1.2M shares

The shares are held by ARCH Venture Fund XIV, while its general partners may be deemed beneficial owners and disclaim ownership except to the extent of any pecuniary interest.

Available on EDGAR 11/02/2026 - 09:46 PM EST Accepted by SEC EDGAR 11/02/2026 - 09:46 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Aspen Neuroscience, Inc. (ASPE) reports that ARCH Venture Fund XIV, L.P. purchased 1,200,000 shares of common stock at $15 per share on November 2, 2026, bringing the fund’s reported holdings to 1,200,000 shares. No Rule 10b5-1 plan is reported. The shares are held by the fund; its sole general partner, ARCH Venture Partners XIV, L.P., and that entity’s sole general partner, ARCH Venture Partners XIV, LLC, may be deemed beneficial owners and disclaim beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

Net Buyer: 1,200,000 shares

Net Buy 1 txn

Insider ARCH Venture Partners XIV, L.P., ARCH Venture Partners XIV, LLC, ARCH Venture Fund XIV, L.P., BERNS PAUL L

Role 10% Owner | 10% Owner | 10% Owner | 10% Owner

Bought 1,200,000 shs ($18.00M)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2	1,200,000	$15.00	$18.00M

Holdings After Transaction: Common Stock — 1,200,000 shares (Direct)

Holdings Before and After: Common Stock, 0 to 1,200,000 shares (Direct)

Footnotes (2)

1. F1. Securities held by ARCH Venture Fund XIV, L.P. ("ARCH XIV"). ARCH Venture Partners XIV, L.P. ("AVP XIV LP") is the sole general partner of ARCH XIV.
2. F2. ARCH Venture Partners XIV, LLC ("AVP XIV LLC") is the sole general partner of AVP XIV LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (collectively, the "AVP XIV LLC Committee Members") comprise the investment committee of AVP XIV LLC. Each of AVP XIV LP and AVP XIV LLC may be deemed to beneficially own the shares held by ARCH XIV, and each of the AVP XIV LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIV. Each of AVP XIV LP, AVP XIV LLC and the AVP XIV LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Key Figures

Common shares purchased: 1,200,000 shares Purchase price: $15 per share Reported holdings after purchase: 1,200,000 shares

3 metrics

Common shares purchased 1,200,000 shares ARCH Venture Fund XIV, L.P.; November 2, 2026

Purchase price $15 per share November 2, 2026

Reported holdings after purchase 1,200,000 shares ARCH Venture Fund XIV, L.P.

Key Terms

beneficial ownership, pecuniary interest, sole general partner

3 terms

beneficial ownership regulatory

"disclaims beneficial ownership except to the extent"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"their pecuniary interest therein, if any"

sole general partner financial

"is the sole general partner of ARCH XIV"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ASPE shares did ARCH Venture Fund XIV buy, and at what price?

ARCH Venture Fund XIV, L.P. purchased 1,200,000 shares of Aspen Neuroscience common stock at $15 per share on November 2, 2026. Its reported holdings following the purchase were 1,200,000 shares, and no Rule 10b5-1 plan is reported.

Who holds the ASPE shares reported in the purchase?

The shares are held by ARCH Venture Fund XIV, L.P. ARCH Venture Partners XIV, L.P., its sole general partner, and ARCH Venture Partners XIV, LLC, the sole general partner of ARCH Venture Partners XIV, L.P., may be deemed to beneficially own the shares; each disclaims beneficial ownership except to the extent of any pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARCH Venture Partners XIV, L.P.

(Last) (First) (Middle)

8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO ILLINOIS 60631

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aspen Neuroscience, Inc. [ ASPE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		P		1,200,000	A	$15	1,200,000	D(1)(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

ARCH Venture Partners XIV, L.P.

(Last) (First) (Middle)

8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO ILLINOIS 60631

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ARCH Venture Partners XIV, LLC

(Last) (First) (Middle)

8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO ILLINOIS 60631

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ARCH Venture Fund XIV, L.P.

(Last) (First) (Middle)

8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO ILLINOIS 60631

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

BERNS PAUL L

(Last) (First) (Middle)

8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO ILLINOIS 60631

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Securities held by ARCH Venture Fund XIV, L.P. ("ARCH XIV"). ARCH Venture Partners XIV, L.P. ("AVP XIV LP") is the sole general partner of ARCH XIV.

2. ARCH Venture Partners XIV, LLC ("AVP XIV LLC") is the sole general partner of AVP XIV LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (collectively, the "AVP XIV LLC Committee Members") comprise the investment committee of AVP XIV LLC. Each of AVP XIV LP and AVP XIV LLC may be deemed to beneficially own the shares held by ARCH XIV, and each of the AVP XIV LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIV. Each of AVP XIV LP, AVP XIV LLC and the AVP XIV LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Remarks:

This Form 4 is one of two reports being filed jointly by ARCH Venture Fund X, L.P., ARCH Venture Partners X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, Robert Nelsen, Steven Gillis, Keith Crandell, and Kristina Burow, AVF XIV, AVP XIV LP, AVP XIV LLC, and Paul Berns (collectively, the "Reporting Persons").

	ARCH Venture Fund XIV, L.P. By: ARCH Venture Partners XIV, L.P., its General Partner By: ARCH Venture Partners XIV, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact	11/02/2026
	ARCH Venture Partners XIV, L.P. By: ARCH Venture Partners XIV, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact	11/02/2026
	ARCH Venture Partners XIV, LLC By: /s/ Mark McDonnell, as Attorney-in-Fact	11/02/2026
	/s/ Paul Berns, By: Mark McDonnell, as attorney-in-fact	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)